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List of Abbreviations 
NT: Neurotensin 
NAFLD: non-alcoholic fatty liver disease  
NASH: steatohepatitis  
Pro-NT: proneurotensin 1-117  
T2D: type 2 diabetes 
BMI: body mass index  
SBP systolic blood pressure  
DBP: diastolic blood pressure 
OGTT: oral glucose tolerance test  
FBG: Fasting blood glucose  
HbA1c: glycosylated hemoglobin  
HDL: high-density lipoprotein cholesterol  
AST: aspartate aminotransferase  
ALT: alanine aminotransferase  
FBI: fasting blood insulin 
LDL: low-density lipoprotein cholesterol 
HOMA-IR: insulin resistance  
HOMA-β: homeostasis model assessment of insulin secretion  
NAS: NAFLD activity score  
SAF: Steatosis Activity Fibrosis score 
AUROC: area under receiver-operating characteristic curve 
Context Neurotensin (NT) is an intestinal peptide released by fat ingestion and promoting 
lipids absorption; higher circulating NT levels associate with type 2 diabetes (T2D), obesity 
and cardiovascular disease. Whether NT is related to non-alcoholic fatty liver disease 
(NAFLD) and steatohepatitis (NASH) has not been fully investigated.   
Objective To study the relationship between plasma proneurotensin1-117 (pro-NT), a stable 
fragment of the NT precursor hormone, and the presence/severity of NAFLD/NASH and to 
unravel correlates of increased pro-NT levels.  
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Design/Setting/Participants For this cross-sectional study, sixty obese individuals 
undergoing bariatric surgery for clinical purposes were recruited. The association between 
pro-NT and NAFLD was further investigated in 260 consecutive subjects referring to our 
outpatient clinics for metabolic evaluations including liver ultrasonography. Study population 
underwent complete metabolic characterization; in the obese cohort, liver biopsies were 
performed during surgery.  
Main outcome measures Plasma pro-NT levels in relation to NAFLD/NASH. 
Results Obese subjects with biopsy-proven NAFLD (53%) had significantly higher plasma 
pro-NT than those without NAFLD (183.6±81.4 vs 86.7±56.8 pmol/L, p<0.001). Greater pro-
NT correlated with NAFLD presence (p<0.001) and severity (p<0.001), age, female gender, 
insulin-resistance and T2D. Higher pro-NT predicted NAFLD with AUROC=0.836 
(C.I.95%:0.73-0.94, p<0.001). Belonging to the highest pro-NT quartile correlated with 
increased NAFLD risk (OR:2.62; 95%CI:1.08-6.40), after adjustment for confounders. The 
association between higher pro-NT and NAFLD was confirmed in the second cohort, 
independently from confounders. 
Conclusions Increased plasma pro-NT levels identify the presence/severity of NAFLD; in 
dysmetabolic individuals, NT may specifically promote hepatic fat accumulation though 
mechanisms likely related to increased insulin-resistance. 
This study shows for the first time in humans the existence of a correlation between circulating 
neurotensin and biopsy-proven NAFLD/NASH. 
Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a pathological condition characterized by the 
macrovesicular accumulation of triglycerides within hepatocytes (hepatic steatosis); in a 
number of cases, necro-inflammatory activity and fibrosis coexist (non-alcoholic 
steatohepatitis, NASH); furthermore, cirrhosis and liver failure may occur in 20-25% of 
affected individuals (1, 2). Nowadays, NAFLD represents the most common cause of chronic 
liver disease in developed countries (3), being detectable in 20-30% of general population (4, 
5) in almost 75% of type 2 diabetic (T2D) patients (6, 7) and in up to 90% obese T2D 
individuals (8, 9). In dysmetabolic conditions, NAFLD worsens inflammatory and metabolic 
outcomes (10-12) and is associated with greater prevalence and severity of micro and macro-
vascular complications in patients with T2D (13-15). Indeed, NAFLD is universally 
recognized as an independent risk factor for cardiovascular mortality (16). Nowadays, despite 
the impressively high number of pharmacological interventions proposed, the identification 
of an effective therapy of NAFLD beyond standard lifestyle measures, is still an open issue 
and represents a major challenge (17).  
Neurotensin (NT) is a 13 amino-acid peptide mainly secreted by neuroendocrine cells in 
the small intestine tract (18) and displays an important role in regulating food ingestion and 
fat absorption (19). By doing so, NT influences energy balance and body weight (20). NT 
mainly acts as a neurotransmitter in the central nervous system and as a hormone in the 
periphery, exerting its physiological action by binding the specific NT receptors, NTSR1, 2 
and 3 (21, 22). Experimental evidence has shown that NT/NTSR1 system is involved in the 
adaptive energy balance (23-25); NTSR1 loss of function determined overweight and 
impaired ability to appropriately respond to energy deprivation signals (24), pointing out to a 
crucial role of NT in mediating, among others, leptin (23-25) and ghrelin (25) pathways. 
Indeed, the leptin-mediated systems regulating appetite are controlled by NT expressing 
neurons (23). In the periphery, NT influences body weight by controlling macronutrients 
absorption. Physiology studies described acute increase of intestine NT release immediately 
after food ingestion, directly associated with meal fat content (26). Later on, several data 
have been produced on the role of NT in facilitating lipid digestion and fat absorption in the 
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small intestine (27-29). The refined, complex control of energy balance exerted by NT at 
different levels, provides a possible pathophysiological explanation to the evidence of a 
correlation between its circulating levels and increased prevalence and incidence of obesity-
related diseases (30, 31). In particular, within the large cohort of the Malmö Diet and Cancer 
Study (30), fasting concentration of pro-NT, the circulating peptide secreted at equimolar 
levels to NT, was associated with the incidence of T2D, cardiovascular disease, breast cancer, 
and with total and cardiovascular mortality (30). The association between pro-NT and 
incident major cardiovascular events was, lately, confirmed in the Framingham Heart Study 
Offspring cohort, independently of the presence of traditional cardiovascular risk factors (31). 
Very recently, an extensive investigation on a putative causal role of NT in determining 
aberrant fat accumulation and metabolic diseases has been carried out (29), showing reduced 
intestinal fat absorption, along with protection from obesity and NAFLD, in NT-deficient 
mice fed with high fat diet. Furthermore, the same study demonstrated that, in humans, higher 
plasma pro-NT levels were associated with features of insulin resistance and doubled the risk 
of developing obesity later in life non-obese subjects. 
Despite the strong rationale behind and encouraging evidence from animal models, little 
is known on circulating pro-NT levels and NAFLD/NASH in humans. Therefore, aims of this 
study were to investigate the relationship between plasma NT concentration and the presence 
and severity of NAFLD/NASH in adult obese individuals with or without T2D and to 
determine clinical correlates of impaired NT levels in this population.  
Materials and Methods 
Population 
For these purposes, we recruited sixty consecutive obese candidates to bariatric surgery 
referring to the Endocrinology and Diabetes outpatient clinics of Sapienza University of 
Rome for pre-operative evaluations. The presence of an association between circulating pro-
NT levels and NAFLD was further explored in a cohort of individuals (n= 260) referring to 
the same outpatient clinics for metabolic evaluations, including upper abdomen US for 
assessing the presence of fatty liver. To be eligible for the study, all the study participants had 
to fulfil the following criteria: male and female aged between 20 and 65 years, no history of 
current or past excessive alcohol drinking, as defined by an average daily consumption of 
alcohol > 30 gr/day in men and > 20 gr/day in women; negative tests for the presence of 
hepatitis B surface antigen and antibody to hepatitis C virus; absence of history and findings 
consistent with cirrhosis and other causes of liver diseases (autoimmune hepatitis, 
hemochromatosis, Wilson’s disease), no treatment with drugs known to cause liver steatosis 
(e.g., corticosteroids, estrogens, methotrexate, tetracycline, calcium channel blockers, or 
amiodarone). Furthermore, patients belonging to the morbidly obese cohort, had clinical 
indication to bariatric surgery. All the participants underwent a complete work-up including 
medical history collection, clinical examination, anthropometric measurements and 
laboratory tests.  
Clinical and laboratory assessment 
Weight and height were measured with patients wearing light clothing and no shoes. The 
body mass index (BMI, kg/m2) was calculated as weight in kilograms divided by the square 
of the height in meters. Waist circumference was measured midway between the 12th rib and 
the iliac crest. Systemic systolic (SBP) and diastolic (DBP) blood pressure were measured 
after 5 minutes resting; three measurements were taken and the average of the second and 
third measurements was recorded and used in the analyses. Individuals without a previously 
formulated diagnosis of diabetes mellitus underwent standard oral glucose tolerance test 
(OGTT) measuring blood glucose and insulin at baseline and 30, 60, 90 and 120 minutes 
after glucose ingestion. A 12-hour overnight fasting blood sample was obtained before 
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surgery for metabolic profiling. Fasting blood glucose (FBG, mg/dL), glycosylated 
hemoglobin (HbA1c, % - mmol/mol), total cholesterol (mg/dL), high-density lipoprotein 
cholesterol (HDL, mg/dL), triglycerides (mg/dL), aspartate aminotransferase (AST, IU/L), 
alanine aminotransferase (ALT, IU/L) and creatinine (mg/dL) were measured by centralized 
standard methods. Insulin (FBI, lU/mL) was measured by radioimmunoassay (ADVIA 
Insulin Ready Pack 100; Bayer Diagnostics, Milan, Italy), with intra- and inter-assay 
coefficients of variation <5%. Low-density lipoprotein (LDL) cholesterol value was obtained 
using Friedwald formula. 
For our purposes, we measured circulating concentration of pro-NT on plasma frozen 
immediately after separation and stored at -80°C. Pro-NT was measured using a 
chemiluminometric sandwich immunoassay to detect pro-NT amino acids 1–117 as described 
previously (32). The analytical assay sensitivity (mean relative light units of 10 
determinations sheep serum plus 2 standard deviations) was 4.8 pmol proNT/l. The inter 
assay (10 assay runs) coefficient of variability was 6.2% at 48 pmol proNT/l and 4,1% at 191 
pmol/L. Recovery and dilution was > 85% in a measurement range of 25-850 pmol/l. 
The homeostasis model assessment of insulin resistance (HOMA-IR) and insulin 
secretion (HOMA-β %) were calculated as previously described (33). Diabetes mellitus was 
defined according to the American Diabetes Association 2009 criteria (34) and metabolic 
syndrome (MS) by the modified NCEP ATP-III criteria (35). 
Liver biopsy and histology 
Study patients underwent intraoperative liver biopsy during surgery for sleeve gastrectomy. 
All the procedures were conducted in accordance with recommendations set by the American 
Association for the Study of Liver Diseases (36). Liver fragments were fixed in buffered 
formalin for 2-4 hours and embedded in paraffin, sections were cut and stained with 
hematoxylin and eosin and Masson’s trichrome stains. A single pathologist blinded to 
patients’ medical history and biochemistry performed the overall histological evaluations. A 
minimum biopsy length of 15 mm or the presence of 10 complete portal tracts was required 
(37). Liver biopsy samples were classified based on the presence of NASH by Brunt 
definition (38) and graded according to the NAFLD activity score (NAS) (39); fibrosis was 
quantified on the basis of the NASH Clinical Research Network Scoring System Definition 
(39). 
NAFLD assessment in individuals not candidate to surgery 
In individuals not candidate to surgery, NAFLD was evaluated through liver ultrasonography 
(US). This was performed using an Esaote Medica instrument with a convex 3,5 MHz probe 
by the same operator blinded to laboratory values. Liver steatosis was defined according to 
Saverymuttu et al. (40) on the basis of abnormally intense, high level echoes arising from the 
hepatic parenchyma, liver-kidney difference in echo amplitude, echo penetration into deep 
portion of the liver and clarity of liver blood vessel structure. 
Statistics 
SPSS version 23 was used to perform statistical analyses. Continuous variables are reported 
as the mean ± standard deviation (SD), and categorical variables are reported as percentages. 
Student's T-test for continuous variables, χ2 test for categorical variables were used to 
compare mean values between two independent groups; skewed variables underwent natural 
logarithmic transformations before performing the analyses. Correlations between parameters 
were explored by Pearson’s (continuous variables) or Spearman’s (categorical variables) 
coefficients or by age-, gender-and BMI adjusted partial correlations. Histological parameters 
are expressed by ordinal scales for NAFLD Activity Score (NAS) and Steatosis Activity 
Fibrosis score (SAF) (38). NAS score was use as continuous scale for activity assessment, 
comparisons between >2 were obtained by Bonferroni-adjusted ANOVA test. The predictive 
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value of plasma pro-NT for NAFLD identification was estimated by the area under receiver-
operating characteristic curve (AUROC), with a 95% confidence interval (C.I.). Multivariate 
logistic regression models were built to identify determinants of NAFLD (yes/no, dependent 
variable) in our study population, entering all the variables significantly associated at the 
bivariate analyses as covariates. Data are shown as mean ± standard deviation. For all the 
above, A two-tailed P value < 0.05 was considered statistically significant. 
At the best of our knowledge, no study has investigated so far circulating pro-NT levels in 
relation to NAFLD. Therefore, in order to confirm the statistical power of this study, we 
performed a post-hoc sample size calculation considering mean pro-NT concentration in 
subjects with and without NAFLD and we obtained that fifteen patients per subgroup would 
have been enough to reach the statistical significance with power= 90% and α error= 0.05. 
For all the above, p value < 0.05 was considered statistically significant. 
The study protocol was reviewed and approved by the Ethics Committee of Policlinico 
Umberto I, Sapienza University of Rome and conducted in conformance with the Helsinki 
Declaration. Written consent was obtained from all patients before the study. 
Results 
Pro-NT and biopsy-proven NAFLD/NASH 
Within our study population, thirty-two subjects out of sixty subjects (53%) had histological 
features of NAFLD; clinical and biochemical characteristics of the study population in 
relation to the presence of NAFLD are shown in Table 1, along with results from age-, 
gender- and BMI-adjusted partial correlation analyses.  
Plasma pro-NT levels were significantly higher in NAFLD patients than in subjects 
without NAFLD (183.6 ± 81.4 vs 86.7  ± 56.8 pmol/L, p<0.001; figure 1A) and directly 
correlated with the diagnosis of NASH, severity of steatosis, intrahepatocyte ballooning and, 
subsequently, higher NAS score and SAF score, as shown in Table 2. In particular, pro-NT 
levels were significantly higher throughout increasing NAS score severity subgroups 
(p<0.001, Figure 1B) and this association persisted strongly significant after correcting for 
sex and age at the partial correlation analysis (r= 0.62, p< 0.001). Among clinical parameters, 
greater pro-NT levels correlated with age, female gender, T2D and parameters associated 
with insulin-resistance and impaired glucose metabolism, as detailed in table 2. No 
association was found, instead, with BMI and waist circumference. 
The presence of biopsy-proven NAFLD was associated with female sex (r= 0.31, p= 
0.02), higher pro-NT (r= 0.56, p<0.001), ALT (r= 0.30, p= 0.03) and lower AST/ALT (r= -
0.37, p= 0.009). At the multivariate logistic regression analysis, higher pro-NT levels were 
associated with biopsy-proven NAFLD independently from possible confounders (Table 3). 
Higher pro-NT concentration predicts the presence of NAFLD with AUROC= 0.836 
(95%C.I.: 0.73- 0.94, p<0.001, figure 2).  
Pro-NT and US-detected NAFLD 
Out of the 260 consecutive individuals undergoing metabolic characterization and liver US, 
60% (n= 157) had a diagnosis of NAFLD; subjects with NAFLD had significantly higher 
plasma pro-NT levels than non-NAFLD individuals (190.78 ± 116.6 vs 154.3 ± 88.9 pmol/L, 
p= 0.003). Clinical and metabolic characteristics of this study cohort, according to the 
presence of NAFLD, are shown as Supplementary Data S1. At the bivariate analyses, greater 
pro-NT levels correlated with the presence of NAFLD (r= 0.19, p= 0.002), T2D (r= 0.25, p= 
0.001) and female gender (r= 0.15, p= 0.05), whereas a trend towards positive association -
not reaching statistical significance- was observed between higher pro-NT levels and the 
number of MS components (r= 0.11, p= 0.08). No association was found between pro-NT, 
age and indexes of body adiposity, such as BMI and waist circumference (Supplementary 
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Data S2). The multivariate logistic regression analysis confirmed that higher pro-NT 
correlated with the presence of NAFLD independently from age, gender, presence of T2D 
and number of MS components (Supplementary Data S3). 
Discussion 
This study demonstrates the existence of an association between circulating pro-NT levels 
and the presence and severity of biopsy-proven NAFLD and NASH in obese adults. The 
relationship between higher pro-NT and NAFLD was confirmed in a larger population of 
adults with diagnosis of fatty liver made with US examination but without signs of severe 
liver damage, thus reinforcing the evidence obtained in patients evaluated with liver 
histology.  
Recently Li J et al. (29), in an extensive investigation on mechanisms behind the 
association between higher pro-NT and the development of obesity and cardio-metabolic 
diseases (30, 31), found significantly reduced intestinal fat absorption in NT-deficient mice 
and protection towards high fat diet-induced obesity, hepatic steatosis and insulin-resistance 
in comparison with the wild-type (29). As NT-deficient mice (29), NTR3-deficient mice are 
protected from high fat diet-induced obesity and fatty liver (41), indicating that NT-induced 
hepatic fat accumulation is mediated by both NTR1 and NTR3. In our study, higher pro-NT 
correlated with T2D and signatures of impaired glucose metabolism and insulin-resistance, 
but not with adiposity per se, in line with previous reports (30, 31). NAFLD represents an 
established cardiovascular risk factor (16) and may determine and worsen insulin-resistance, 
systemic inflammation (10) and metabolic complications of obesity (11, 12). Indeed, we 
observed a linear association between pro-NT, hepatic damage in NASH and parameters 
related to glucose metabolism impairment.  
A possible weakness of this novel observation can be represented by the limited sample 
size of the cohort undergoing liver biopsy. However, obtaining samples for liver histology 
implies the use of invasive procedures, reasonably representing per se a limiting factor for 
study enrolment. 
On the other hand, all the study participants underwent accurate metabolic 
characterization; the study was monocentric and all the procedures were performed by the 
same operator, strengthening the study design and the reliability of our results. Finally, the 
findings obtained in the main study population have been confirmed in an additional cohort 
undergoing hepatic US and metabolic phenotyping, reinforcing our results and making them 
applicable also in individuals with different degree of body adiposity and non-clinically 
relevant hepatic damage. Indeed, the association between plasma pro-NT and different 
measurements of NAFLD broadens the clinical utility of our findings. 
 Despite the cross-sectional design of our study does not allow to establish a causal nexus 
between these findings, it is plausible to hypothesize that increased pro-NT levels facilitate 
the absorption of fatty acids from small intestine promoting fat accumulation in specific sites, 
such as the liver. Thus, NT may lead to NAFLD/NASH in a dose-dependent manner and may 
act both directly and indirectly –through hepatic fat accumulation- in worsening insulin 
resistance and metabolic profile. Gut hormones regulation is currently considered as an 
appealing target for anti-obesity treatment (42, 43); in this context, our findings are intriguing 
and may put the basis for further investigation on novel therapeutic approaches to NAFLD. 
Moreover, pro-NT may represent a novel biomarker of NAFLD in individuals with and 
without obesity, with relevant implications in clinical practice. In conclusion, our study 
demonstrates for the first time that pro-NT levels predict the presence of biopsy-proven 
NAFLD in obese subjects and are associated with insulin resistance and detrimental 
metabolic profile. Studies on larger cohorts and longitudinal design are warranted to 
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investigate the possible role of NT in the development, progression and prognosis of NAFLD 
and NASH. 
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Figure 1. Plasma pro-NT levels according to the presence of NAFLD (A) and NAS score 
(B). *T-Student’s test, §ANOVA test; Bonferroni comparison between subgroups: NAS ≤ 2 
vs #3-4, ^vs ≥ 5; NAS 3-4 vs °≥ 5.  
Figure 2. Pro-NT AUROC for NAFLD. 
Table 1. Clinical and biochemical characteristic of patients with and without biopsy-proven 
NAFLD. Student’s T test. *Chi-square test. § Student’s t-test. P values refer to the age-, 
gender-and BMI-adjusted partial correlation analyses, unless differently specified.  
 no NAFLD (n=28) NAFLD (n=32) Partial correlation coefficient (adjusted for age, 
gender, BMI) 
P-value 
Age (years) 40.5 ± 12 43.2 ± 9.4  - n.s.§ 
Gender (M%) 61.5% 32%  - 0.03* 
BMI (Kg/m2) 43.5±6.3 41.8±4.3  - n.s.§ 
Waist circumference (cm) 129.4±16.9 128±7.7 -0.31 0.20 
SBP (mmHg) 133±8.4 124.4±7.7 -0.26 0.17 
DBP (mmHg) 85±8.7 85.9±22.1 -0.07 0.72 
Total Cholesterol (mg/dl) 213±140.4 171±126 -0.32 0.07 
HDL-C (mg/dl) 52±8.8 46.7±10.2 -0.05 0.77 
LDL-C (mg/dl) 141.9±26.6 121.1±22.3 -0.40 0.03 
Triglycerides (mg/dl) 118±70.3 134±43.1 0.34 0.056 
FBG (mg/dl) 102.1±45.3 102.5±17.3 0.41 0.017 
HbA1c (%/mmol/mol) 5.2±0.25 5.5±0.48 0.33 0.07 
AST (IU/l) 22.1±7.9 24.1±10.4 0.14 0.44 
ALT (IU/l) 25.3±17.2 32.7±15.6 0.37 0.03 
AST/ALT 0.99±0.3 0.78±0.2 -0.45 0.008 
FBI (µU/l) 20.3±13.2 16±11.2 0.24 0.23 
HOMA-IR 3.6±3.1 4.1±3.2 0.29 0.14 
HOMA-β% 123±140.4 171±126 0.09 0.67 
T2D (%) 11% 13% 0.23 0.19 
Pro-NT (pmol/L) 86.7±56.8 183.6±81.4 0.35 <0.001§; 0.039 
Table 2. Pro-NT- Bivariate correlation analyses (Pearson’s coefficient, *Spearman’s 
coefficient, pro-NT is considered as a continue variable) 
 Correlation coefficient p-value 
Age 0.41 0.002 
Gender (M/F) 0.34 0.005* 
BMI  0.03 0.85 
Waist circumference -0.15 0.49 
FBG 0.17 0.19 
FBI 0.54 0.002 
HbA1c 0.62 <0.001 
Total Cholesterol -0.20 0.17 
HDL -0.09 0.54 
LDL -0.28 0.065 
Triglycerides 0.30 0.05 
AST 0.02 0.86 
ALT 0.09 0.56 
Serum creatinine 0.37 0.005 
HOMA-B 0.69 0.003 
HOMA-IR 0.47 0.009 
NAFLD yes/no  0.59 <0.001* 
SAF score 0.36 0.02* 
NAS: steatosis 0.34 0.037* 
NAS: intrahepatocyte ballooning 0.54 <0.001* 
NAS score 0.46 0.003* 
T2D yes/no 0.31 0.02* 
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Table 3. Multivariate logistic regression analysis. The presence of NAFLD is the dependent 
variable. Pro-NT is considered as a continuous variable. 
 B E.S. Wald P value Odd Ratio 95% C.I.  
Inferior Superior 
Age -0.027 0.043 0.378 0.54 0.97 0.89 1.06 
Gender (M/F) -2.146 1.281 2.807 0.09 0.12 0.01 1.44 
AST/ALT -2.527 1.873 1.819 0.18 0.08 0.002 3.14 
ALT (IU/L) -0.010 0.032 0.106 0.74 0.99 0.93 1.05 
Pro-NT (pmol/L) 0.022 0.010 5.094 0.02 1.02 1.003 1.04 
Constant 2.792 3.087 0.818 0.37 16.31   
Cox and Snell R2= 0.412 
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B. 
         
Figure 1. Plasma pro-NT levels according to the presence of NAFLD (A) and NAS score (B). *T-
Student’s test, §ANOVA test; Bonferroni comparison between subgroups: NAS ≤ 2 vs #3-4, ^vs ≥ 5; 
NAS 3-4 vs °≥ 5.  
  
NAS score n. of subjects Pro-NT (pmol/L) P value 
≤ 2 37 92.3 ± 53.8 #0.001; ^<0.001 
3-4 11 182.8 ± 75  #0.001; °0.39 
≥ 5 12 224.6 ± 79.1 ^<0.001; °0.39 
§p<0.001 
                              ≤ 2                 3-4       ≥ 5 
                                               NAS score 
*p<0.001 
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Sensitivity: 84% - Specificity: 75% per plasma pro-NT values > 107 pg/ml 
 
 
 
Figure 2. Pro-NT AUROC for NAFLD. 
 
 
Area under the curve 
Area Standard errora Asintotic 
significanceb 
Asintotic 95%Confidence Interval 
Lower limit Upper limit 
0.836 0.054 <0.001 0.731 0.941 
a. Based on non-parametric assumption 
 
b. Null hypothesis: real area = 0.5 
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